Tauriga Sciences Inc. to Resume the Clinical Development of its Proposed
Share: This Proposed Pharma Grade Version of Tauri-Gum™ is Being Developed Specifically to Target: Patients Subjected to Ongoing Chemotherapy Treatment NEW YORK, NY, Dec. 16, 2020 (GLOBE NEWSWIRE) -- via NewMediaWire -- Tauriga Sciences, Inc. (OTCQB: TAUG) ("Tauriga" or the "Company"), a revenue generating, diversified life sciences company, with a proprietary line of functional "supplement" chewing gums (Flavors: Pomegranate, Blood Orange, Peach-Lemon, Pear Bellini, Mint, Black Currant) as well as two ongoing Biotechnology initiatives, today announced the resumption of clinical develop...
Source: benzinga.com